The Federal Circuit ruled in favor of UC Berkeley, reviving its legal claim to foundational CRISPR gene editing patents. The court found that the Patent Trial and Appeal Board erred in dismissing UC’s evidence that its earlier findings could be applied to genes in plants and animals using routine scientific methods.
